Suppression of autocrine and paracrine functions of basic fibroblast growth factor by stable expression of perlecan antisense cDNA

Molecular and Cellular Biology

Volumn 17, Issue 4, 1997, Pages 1938-1946

  Aviezer, David ^a   Iozzo, Renato V ^b   Noonan, Douglas M ^c   Yayon, Avner ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BASIC FIBROBLAST GROWTH FACTOR; COMPLEMENTARY DNA; HEPARIN; PERLECAN;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL STRAIN 3T3; CELL TRANSFORMATION; DOWN REGULATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA;

EID: 0030945178     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.17.4.1938     Document Type: Article

References (43)

1. Aviezer, D., E. Levy, M. Safran, C. Svahn, E. Buddecke, A. Schmidt, G. David, I. Vlodavsky, and A. Yayon. 1994. Differential structural requirements of heparin and heparan sulfate proteoglycans that promote binding of basic fibroblast growth factor to its receptor. J. Biol. Chem. 269:114-121.
2. Aviezer, D., D. Hecht, M. Safran, M. Eisinger, G. David, and A. Yayon. 1994. Perlecan, basal lamina proteoglycan promotes bFGF-receptor binding, mitogenesis and angiogenesis. Cell 79:1005-1013.
3. Basilico, C., and D. Moscatelli. 1992. The FGF family of growth factors and oncogenes. Adv. Cancer Res. 159:115-165.
4. Becker, D., C. B. Meier, and M. Herlyn. 1989. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J. 8:3685-3691.
5. Brickman, Y. G., M. D. Ford, D. H. Small, P. F. Bartlett, and V. Nurcombe. 1995. Heparan sulfates mediate the binding of basic fibroblast growth factor to a specific receptor on neural precursor cells. J. Biol. Chem. 270:24941-24948.
6. Chakravarti, S., T. Horchar, B. Jefferson, G. W. Laurie, and J. R. Hassell. 1995. Recombinant domain III of perlecan promotes cell attachment through its RGDS sequence. J. Biol. Chem. 270:404-409.
7. Cohen, I. R., A. D. Murdoch, M. F. Naso, D. Marchetti, D. Berd, and R. V. Iozzo. 1994. Abnormal expression of perlecan proteoglycan in metastatic melanomas. Cancer Res. 54:5771-5774.
8. Dotto, P. G., G. Moellmann, S. Gosh, M. Edwards, and R. Halaban. 1989. Transformation of murine melanocytes by bFGF cDNA and oncogenes and selective suppression of the transformed phenotype in a reconstituted cutaneous environment. J. Cell Biol. 109:3115-3128.
9. Folkman, J., and Y. Shing. 1992. Control of angiogenesis by heparin and other sulfated polysaccharides. Adv. Exp. Med. Biol. 313:355-364.
10. Gallagher, J. T. 1994. Heparan sulphates as membrane receptors for the fibroblast growth factors. Eur. J. Clin. Chem. Clin. Biochem. 32:239-247.
11. Guelstein, V. I., T. A. Tchypysheva, V. D. Ermilova, and A. V. Ljubimov. 1993. Myoepithelial and basement membrane antigens in benign and malignant human breast tumors. Int. J. Cancer 53:269-277.
12. Guillonneau, X., J. Tassin, E. Berrou, M. Bryckaert, Y. Courtois, and F. Mascarelli. 1996. In vitro changes in plasma membrane heparan sulfate proteoglycans and in perlecan expression participate in the regulation of fibroblast growth factor 2 mitogenic activity. J. Cell. Physiol. 166:170-187.
13. Guimond, S., M. Maccarana, B. B. Olwin, U. Lindahl, and A. C. Rapraeger. 1993. Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. J. Biol. Chem. 268: 23906-23914.
14. Gunning, P., J. Leavitt, G. Muscat, S. Y. Nig, and L. Kedes. 1987. Differential patterns of transcript accumulation during human myogenesis. Proc. Natl. Acad. Sci. USA 84:4831-4835.
15. Halaban, R., B. S. Kwon, S. Ghosh, P. Delli Bovi, and A. Baird. 1988. bFGF as an autocrine growth factor for human melanomas. Oncogene Res. 3:177-186.
16. Iozzo, R. V., I. R. Cohen, S. Grassel, and A. D. Murdoch. 1994. The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem. J. 302:625-639.
17. Iozzo, R. V. 1984. Biosynthesis of heparan sulfate proteoglycan by human colon carcinoma cells and its localization at the cell surface. J. Cell Biol. 99:403-417.
18. Ishihara, M. 1994. Structural requirements in heparin for binding and activation of FGF-1 and FGF-4 are different from that for FGF-2. Glycobiology 4:817-824.
19. Jalkanen, M., A. Määttä, T. Vihinen, and P. Jaakkola. 1995. Syndecan-1 in growth factor action: an inhibitory loop for FGF-function, p. 17. In Abstracts of the EMBO/NORFA Workshop on Growth Factors and Receptor Kinases, Helsinki, Finland.
20. Kato, M., Y. Koike, S. Suzuki, and K. Kimata. 1988. Basement membrane proteoglycan in various tissues: characterization using monoclonal antibodies to the Engelbreth-Holm-Swarm mouse tumor low density heparan sulfate proteoglycan. J. Cell Biol. 106:2203-2210.
21. Klagsbrun, M. 1989. The fibroblast growth factor family: structural and biological properties. Prog. Growth Factor Res. 1:207-235.
22. Kokenyesi, R., and J. E. Silbert. 1995. Formation of heparan sulfate or chondroitin/dermatan sulfate on recombinant domain I of mouse perlecan expressed in Chinese hamster ovary cells. Biochem. Biophys. Res. Commun. 211:262-267.
23. Kovalszky, I., Z. Schaff, and A. Jeney. 1993. Potential markers (enzymes, proteoglycans) for human liver tumors. Acta Biomed. Ateneo Parmense 64:157-163.
24. Laslett, A. L., J. R. McFarlane, M. T. Hearn, and G. P. Risbridger. 1995. Requirement for heparan sulphate proteoglycans to mediate basic fibroblast growth factor (FGF-2)-induced stimulation of Leydig cell steroidogenesis. J. Steroid Biochem. Mol. Biol. 54:245-250.
25. Maccarana, M., B. Casu, and U. Lindahl. 1993. Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J. Biol. Chem. 268:23898-23905.
26. Mali, M., K. Elenius, H. M. Miettinen, and M. Jalkanen. 1993. Inhibition of basic fibroblast growth factor-induced growth promotion by overexpression of syndecan-1. J. Biol. Chem. 268:24215-24222.
27. Mansukhani, A., P. Dell'Era, D. Moscatelli, S. Kornbluth, H. Hanafusa, and C. Basilico. 1992. Characterization of the murine BEK fibroblast growth factor (FGF) receptor: activation by three members of the FGF family and requirement for heparin. Proc. Natl. Acad. Sci. USA 89:3305-3309.
28. Mathieu, M., E. Chatelain, D. Ornitz, J. Bresnick, I. Mason, P. Kiefer, and C. Dickson. 1995. Receptor binding and mitogenic properties of mouse fibroblast growth factor 3. Modulation of response by heparin. J. Biol. Chem. 270:24197-24203.
29. Murdoch, A. D., G. R. Dodge, I. Cohen, R. S. Tuan, and R. V. Iozzo. 1992. Primary structure of the human heparan sulfate proteoglycan from basement membrane (HSPG2/perlecan). A chimeric molecule with multiple domains homologous to the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor. J. Biol. Chem. 267:8544-8557.
30. Noonan, D. M., A. Fulle, P. Valente, S. Cai, E. Horigan, M. Sasaki, Y. Yamada, and J. R. Hassell. 1991. The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein receptor, and the neural cell adhesion molecule. J. Biol. Chem. 266:22939-22947.
31. Nurcombe, V., M. D. Ford, J. A. Wildschut, and P. F. Bartlett. 1993. Developmental regulation of neural response to FGF-1 and FGF-2 by heparan sulfate proteoglycan. Science 260:103-106.
32. Ornitz, D. M., A. Yayon, J. G. Flanagan, C. M. Svahn, E. Levi, and P. Leder. 1992. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol. Cell. Biol. 12:240-247.
33. Pantoliano, M. W., R. A. Horlick, B. A. Springer, D. D. Van, T. Tobery, D. R. Wetmore, J. D. Lear, A. T. Nahapetian, J. D. Bradley, and W. P. Sisk. 1994. Multivalent ligand-receptor binding interactions in the fibroblast growth factor system produce a cooperative growth factor and heparin mechanism for receptor dimerization. Biochemistry 33:10229-10248.
34. Rapraeger, A. C., S. Guimond, A. Krufka, and B. B. Olwin. 1994. Regulation by heparan sulfate in fibroblast growth factor signaling. Methods Enzymol. 245:219-240.
35. Rapraeger, A. C., A. Krufka, and B. B. Olwin. 1991. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 252:1705-1707.
36. Rescan, P. Y., O. Loreal, J. R. Hassell, Y. Yamada, A. Guillouzo, and B. Clement. 1993. Distribution and origin of the basement membrane component perlecan in rat liver and primary hepatocyte culture. Am. J. Pathol. 142:199-208.
37. Saunders, S., M. Jalkanen, S. O'Farrell, and M. Bernfield. 1989. Molecular cloning of syndecan, an integral membrane proteoglycan. J. Cell Biol. 108: 1547-1556.
38. Spivak, K. T., M. A. Lemmon, I. Dikic, J. E. Ladbury, D. Pinchasi, J. Huang, M. Jaye, J. Schlessinger, and I. Lax. 1994. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell 79:1015-1024.
39. Walker, A., J. E. Turnbull, and J. T. Gallagher. 1994. Specific heparan sulfate saccharides mediate the activity of basic fibroblast growth factor. J. Biol. Chem. 269:931-935.
40. Whitelock, J. M., A. D. Murdoch, R. V. Iozzo, and A. P. Underwood. 1996. The degradation of human endothelial cell-derived perlecan and release of bound bFGF by stromelysin, collagenase, plasmin and heparanases. J. Biol. Chem. 271:10079-10086.
41. Yayon, A., and M. Klagsbrun. 1990. Autocrine regulation of cell growth and transformation by basic fibroblast growth factor. Cancer Metastasis Rev. 9:191-202.
42. Yayon, A., M. Klagsbrun, J. D. Esko, P. Leder, and D. M. Ornitz. 1991. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64:841-848.
43. Zakut, R., R. Perlis, S. Eliyahu, Y. Yarden, D. Givol, S. D. Lyman, and R. Halaban. 1993. KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells. Oncogene 8:2221-2229.